PRTCY (PureTech Health) Other Stockholders Equity: $135.34 Mil (As of Dec. 2025)


PRTCY PureTech Health PLC PRTCY
62 GF Score
Price $17.54
GF Value $70.09
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is PureTech Health Other Stockholders Equity?

PureTech Health PRTCY +1.49% 62 Other Stockholders Equity is $135.34 Mil as of Dec. 2025. GuruFocus rates PRTCY with a GF Score™ of 62/100 and a GF Value™ of $70.09 (Possible Value Trap). The stock has 4 warning signs investors should review.

PureTech Health's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $135.34 Mil.

PureTech Health's quarterly Other Stockholders Equity increased from Dec. 2024 ($133.96 Mil) to Jun. 2025 ($137.71 Mil) but then declined from Jun. 2025 ($137.71 Mil) to Dec. 2025 ($135.34 Mil).

PureTech Health's annual Other Stockholders Equity increased from Dec. 2023 ($129.15 Mil) to Dec. 2024 ($133.96 Mil) and increased from Dec. 2024 ($133.96 Mil) to Dec. 2025 ($135.34 Mil).

PureTech Health Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for PureTech Health's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PureTech Health Other Stockholders Equity Chart

PureTech Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 98.90 124.12 129.15 133.96 135.34

PureTech Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.15 130.15 133.96 137.71 135.34
PRTCY
62GF Score
PureTech Health PLC PRTCY
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PureTech Health Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $135.34 Mil mean?
PureTech Health (PRTCY) has a Other Stockholders Equity of $135.34 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on PureTech Health and its competitors.
Is PureTech Health's Other Stockholders Equity too high?
PureTech Health's current Other Stockholders Equity is $135.34 Mil. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Other Stockholders Equity compare to VRTX and REGN?
PureTech Health's Other Stockholders Equity of $135.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on PureTech Health and its competitors. PureTech Health's current Other Stockholders Equity is $135.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current Other Stockholders Equity is $135.34 Mil. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For PureTech Health (PRTCY), the current Other Stockholders Equity is $135.34 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PureTech Health (PRTCY) Overvalued in 2026?

Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued. The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09. GuruFocus considers PureTech Health to be Possible Value Trap.

Key valuation signals for PRTCY:

  • Other Stockholders Equity: $135.34 Mil
  • GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PureTech Health Business Description

Address 6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score

Get the complete analysis for PRTCY

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.54
Price
$70.09
GF Value